In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis

Medecine et Maladies Infectieuses

Volumn 46, Issue 4, 2016, Pages 220-225

  Lounis, N ^a   Vranckx, L ^a   Gevers, T ^a   Kaniga, K ^b   Andries, K ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bacterial inoculum; Bedaquiline; TMC207

Indexed keywords

BEDAQUILINE; ISONIAZID; POLYPROPYLENE; POLYSORBATE 80; POLYSTYRENE; BOVINE SERUM ALBUMIN; DETERGENT; OVALBUMIN; POLYSORBATE; POLYSTYRENE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN CONTENT; TEMPERATURE; COMPARATIVE STUDY; CULTURE MEDIUM; DEVICES; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; PH; PHARMACOLOGY; PROCEDURES;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; CULTURE MEDIA; DETERGENTS; DIARYLQUINOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OVALBUMIN; POLYPROPYLENES; POLYSORBATES; POLYSTYRENES; SERUM ALBUMIN, BOVINE; TEMPERATURE;

EID: 84974703396     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2016.04.007     Document Type: Article

References (24)

1. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W., Neefs J.M., Winkler H., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
2. Huitric E., Verhasselt P., Andries K., Hoffner S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007, 51:4202-4204.
3. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006, 50:3543-3547.
4. Lenaerts A.J., Hoff D., Aly S., Ehlers S., Andries K., Cantarero L., et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007, 51:3338-3345.
5. Shang S., Shanley C.A., Caraway M.L., Orme E.A., Henao-Tamayo M., Hascall-Dove L., et al. Activities of TMC207, rifampin, and pyrazinamid against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 2011, 55:124-131.
6. Rustomjee R., Diacon A.H., Allen J., Venter A., Reddy C., Patientia R.F., et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:2831-2835.
7. Diacon A.H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New Engl J Med 2009, 360:2397-2405.
8. Diacon A.H., Pym A., Grobusch M.P., de los Rios J.M., Gotuzzo E., Vasilyeva I., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New Engl J Med 2014, 371:723-732.
9. Kaneko T., Cooper C., Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem 2011, 11:1373-1400.
10. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 11:537-544.
11. Kaniga K., Cirillo D.M., Hoffner S., Ismail N.A., Lounis N., Metchock B., et al. Bedaquiline minimal inhibitory concentration quality control ranges for drug-susceptibility testing in a multi-laboratory study. Int J Tuberc Lung Dis 2015, 19(Suppl 2):S200. [PC-806-04].
12. Rio-Marques L., Hartke A., Bizzini A. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Microb Drug Resist 2014, 20:539-543.
13. Truffot-Pernod C., Ji B., Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991, 35:1677-1678.
14. Figura N., Marcolongo R., Cavallo G., Santucci A., Collodel G., Spreafico A., et al. Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study. BMC Microbiol 2012, 12.
15. Schmidt S., Rock K., Sahre M., Burkhardt O., Brunner M., Lobmeyer M.T., et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother 2008, 52:3994-4000.
16. Herbert D., Paramasivan C.N., Venkatesan P., Kubendiran G., Prabhakar R., Mitchison D.A. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996, 40:2296-2299.
17. Rennie R.P., Koeth L., Jones R.N., Fritsche T.R., Knapp C.C., Killian S.B., et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 2007, 45:3151-3154.
18. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008, World Health Organization, Geneva, Switzerland, [http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf (accessed August 2015)].
19. Grant S.S., Kaufmann B.B., Chand N.S., Haseley N., Hung D.T. Eradication of bacterial persisters with antibiotic generated hydroxyl radicals. Proc Natl Acad Sci USA 2012, 109:12147-12152.
20. Dhillon J., Fourie P.B., Mitchison D.A. Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media. J Antimicrob Chemother 2014, 69:437-440.
21. Jenkins C., Bacon J., Allnutt J., Hatch K.A., Bose A., O'Sullivan D.M., et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother 2009, 63:1118-1120.
22. Sader H.S., Rhomberg P.R., Flamm R.K., Jones R.N. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymixin B and colistin. Diagn Microbiol Infect Dis 2012, 74:412-414.
23. Arhin F.F., Sarmiento I., Belley A., McKay G.A., Draghi D.C., Grover P., et al. Effect of polysorbate on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008, 52:1597-1603.
24. Lounis N., Gevers T., Van Den Berg J., Verhaegue T., van Heeswijk R., Andries K. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J Clin Microbiol 2008, 46:2212-2215.